Characterization of Interchanging Incretin Analogs in Clinical Practice: A Descriptive Report.

Hvisdas CM, Goode ND, Kim DH, Silvey MJ, Flood JJ

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists15 Oct 2024

PMID39414234DOI10.1016/j.eprac.2024.09.117PepBankPUB-39414234

Publisher page PubMedAsk about this study

Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone14

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In adult outpatients, pooled incretin analog interchanges were tolerated by 96% of patients.
In plain wordsIn adult outpatients, 96% tolerated pooled incretin drug switches, which included dulaglutide regimens.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicablePooled interchange tolerability
Study
n = 156
Outcome group
Adverse events · Whole body
Measurements
Tolerability
96%
pooled interchanges
Source sentences
Summary
It was determined that 96% of patients tolerated the incretin analog interchange.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective chart review of adult patients receiving care through a participating family medicine or endocrinology clinic between January 1, 2022, and November 30, 2022 at a major academic medical center.
Summary · context
The most common interchanges were dulaglutide 4.5 mg to tirzepatide 7.5 mg, dulaglutide 4.5 mg to tirzepatide 10 mg, and dulaglutide 3 mg to tirzepatide 7.5 mg.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3941423401
02HumanNot a test of Tirzepatide aloneObservational studySafety outcome
In adult outpatients, pooled incretin analog interchanges were tolerated by 96% of patients.
In plain wordsIn adult outpatients, 96% tolerated pooled incretin drug switches, which included tirzepatide regimens.
Peptide
Tirzepatide
Outcome
Not applicablePooled interchange tolerability
Study
n = 156
Outcome group
Adverse events · Whole body
Measurements
Tolerability
96%
pooled interchanges
Source sentences
Summary
It was determined that 96% of patients tolerated the incretin analog interchange.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective chart review of adult patients receiving care through a participating family medicine or endocrinology clinic between January 1, 2022, and November 30, 2022 at a major academic medical center.
Summary · context
The most common interchanges were dulaglutide 4.5 mg to tirzepatide 7.5 mg, dulaglutide 4.5 mg to tirzepatide 10 mg, and dulaglutide 3 mg to tirzepatide 7.5 mg.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3941423402
03HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In adult outpatients, seven patients did not tolerate pooled incretin analog interchange.
In plain wordsIn adult outpatients, seven patients did not tolerate pooled incretin drug switches, which included dulaglutide regimens.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableInterchange intolerance
Study
n = 156
Outcome group
Adverse events · Whole body
Measurements
Patients not tolerating interchange
7 patients
pooled interchanges
Source sentences
Summary
Seven patients did not tolerate incretin analog interchange.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective chart review of adult patients receiving care through a participating family medicine or endocrinology clinic between January 1, 2022, and November 30, 2022 at a major academic medical center.
Summary · context
The most common interchanges were dulaglutide 4.5 mg to tirzepatide 7.5 mg, dulaglutide 4.5 mg to tirzepatide 10 mg, and dulaglutide 3 mg to tirzepatide 7.5 mg.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3941423405
04HumanNot a test of Tirzepatide aloneObservational studySafety outcome
In adult outpatients, seven patients did not tolerate pooled incretin analog interchange.
In plain wordsIn adult outpatients, seven patients did not tolerate pooled incretin drug switches, which included tirzepatide regimens.
Peptide
Tirzepatide
Outcome
Not applicableInterchange intolerance
Study
n = 156
Outcome group
Adverse events · Whole body
Measurements
Patients not tolerating interchange
7 patients
pooled interchanges
Source sentences
Summary
Seven patients did not tolerate incretin analog interchange.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective chart review of adult patients receiving care through a participating family medicine or endocrinology clinic between January 1, 2022, and November 30, 2022 at a major academic medical center.
Summary · context
The most common interchanges were dulaglutide 4.5 mg to tirzepatide 7.5 mg, dulaglutide 4.5 mg to tirzepatide 10 mg, and dulaglutide 3 mg to tirzepatide 7.5 mg.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3941423406
05HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In adult outpatients undergoing pooled incretin analog interchange, five patients experienced gastrointestinal effects.
In plain wordsIn adult outpatients, five patients reported stomach or bowel effects after pooled drug switches that included dulaglutide regimens.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableGastrointestinal effects after interchange
Study
n = 156
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Patients with gastrointestinal effects
5 patients
pooled interchanges
Source sentences
Summary
Five experienced gastrointestinal effects and 2 experienced injection site reactions.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective chart review of adult patients receiving care through a participating family medicine or endocrinology clinic between January 1, 2022, and November 30, 2022 at a major academic medical center.
Summary · context
The most common interchanges were dulaglutide 4.5 mg to tirzepatide 7.5 mg, dulaglutide 4.5 mg to tirzepatide 10 mg, and dulaglutide 3 mg to tirzepatide 7.5 mg.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3941423407
06HumanNot a test of Tirzepatide aloneObservational studySafety outcome
In adult outpatients undergoing pooled incretin analog interchange, five patients experienced gastrointestinal effects.
In plain wordsIn adult outpatients, five patients reported stomach or bowel effects after pooled drug switches that included tirzepatide regimens.
Peptide
Tirzepatide
Outcome
Not applicableGastrointestinal effects after interchange
Study
n = 156
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Patients with gastrointestinal effects
5 patients
pooled interchanges
Source sentences
Summary
Five experienced gastrointestinal effects and 2 experienced injection site reactions.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective chart review of adult patients receiving care through a participating family medicine or endocrinology clinic between January 1, 2022, and November 30, 2022 at a major academic medical center.
Summary · context
The most common interchanges were dulaglutide 4.5 mg to tirzepatide 7.5 mg, dulaglutide 4.5 mg to tirzepatide 10 mg, and dulaglutide 3 mg to tirzepatide 7.5 mg.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3941423408
07HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In adult outpatients undergoing pooled incretin analog interchange, two patients experienced injection site reactions.
In plain wordsIn adult outpatients, two patients reported injection site reactions after pooled drug switches that included dulaglutide regimens.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableInjection site reactions after interchange
Study
n = 156
Outcome group
Adverse events · Whole body
Measurements
Patients with injection site reactions
2 patients
pooled interchanges
Source sentences
Summary
Five experienced gastrointestinal effects and 2 experienced injection site reactions.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective chart review of adult patients receiving care through a participating family medicine or endocrinology clinic between January 1, 2022, and November 30, 2022 at a major academic medical center.
Summary · context
The most common interchanges were dulaglutide 4.5 mg to tirzepatide 7.5 mg, dulaglutide 4.5 mg to tirzepatide 10 mg, and dulaglutide 3 mg to tirzepatide 7.5 mg.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3941423409
08HumanNot a test of Tirzepatide aloneObservational studySafety outcome
In adult outpatients undergoing pooled incretin analog interchange, two patients experienced injection site reactions.
In plain wordsIn adult outpatients, two patients reported injection site reactions after pooled drug switches that included tirzepatide regimens.
Peptide
Tirzepatide
Outcome
Not applicableInjection site reactions after interchange
Study
n = 156
Outcome group
Adverse events · Whole body
Measurements
Patients with injection site reactions
2 patients
pooled interchanges
Source sentences
Summary
Five experienced gastrointestinal effects and 2 experienced injection site reactions.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective chart review of adult patients receiving care through a participating family medicine or endocrinology clinic between January 1, 2022, and November 30, 2022 at a major academic medical center.
Summary · context
The most common interchanges were dulaglutide 4.5 mg to tirzepatide 7.5 mg, dulaglutide 4.5 mg to tirzepatide 10 mg, and dulaglutide 3 mg to tirzepatide 7.5 mg.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3941423410
09HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In adult outpatients undergoing pooled incretin analog interchange, no patients missed an incretin analog dose.
In plain wordsIn adult outpatients, no patients missed a dose during pooled drug switches that included dulaglutide regimens.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableTreatment interruption
Study
n = 156
Outcome group
Patterns of use · Whole body
Source sentences
Summary
During this study, no patients experienced interruption of therapy defined as missing a dose of incretin analog.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective chart review of adult patients receiving care through a participating family medicine or endocrinology clinic between January 1, 2022, and November 30, 2022 at a major academic medical center.
Summary · context
The most common interchanges were dulaglutide 4.5 mg to tirzepatide 7.5 mg, dulaglutide 4.5 mg to tirzepatide 10 mg, and dulaglutide 3 mg to tirzepatide 7.5 mg.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3941423413
10HumanNot a test of Tirzepatide aloneObservational studyOther
In adult outpatients undergoing pooled incretin analog interchange, no patients missed an incretin analog dose.
In plain wordsIn adult outpatients, no patients missed a dose during pooled drug switches that included tirzepatide regimens.
Peptide
Tirzepatide
Outcome
Not applicableTreatment interruption
Study
n = 156
Outcome group
Patterns of use · Whole body
Source sentences
Summary
During this study, no patients experienced interruption of therapy defined as missing a dose of incretin analog.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective chart review of adult patients receiving care through a participating family medicine or endocrinology clinic between January 1, 2022, and November 30, 2022 at a major academic medical center.
Summary · context
The most common interchanges were dulaglutide 4.5 mg to tirzepatide 7.5 mg, dulaglutide 4.5 mg to tirzepatide 10 mg, and dulaglutide 3 mg to tirzepatide 7.5 mg.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3941423414
11HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In adult outpatients, pooled common dulaglutide-to-tirzepatide switches had 93% tolerability.
In plain wordsIn adult outpatients, 93% tolerated the pooled common switches from dulaglutide to tirzepatide.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableCommon dulaglutide-to-tirzepatide switches tolerability
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Tolerability
93%
common switches
Source sentences
Summary
These interchanges made up 37.3% of the total population and were observed to have 93% tolerability.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective chart review of adult patients receiving care through a participating family medicine or endocrinology clinic between January 1, 2022, and November 30, 2022 at a major academic medical center.
Summary · context
The most common interchanges were dulaglutide 4.5 mg to tirzepatide 7.5 mg, dulaglutide 4.5 mg to tirzepatide 10 mg, and dulaglutide 3 mg to tirzepatide 7.5 mg.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3941423403
12HumanNot a test of Tirzepatide aloneObservational studySafety outcome
In adult outpatients, pooled common dulaglutide-to-tirzepatide switches had 93% tolerability.
In plain wordsIn adult outpatients, 93% tolerated the pooled common switches from dulaglutide to tirzepatide.
Peptide
Tirzepatide
Outcome
Not applicableCommon dulaglutide-to-tirzepatide switches tolerability
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Tolerability
93%
common switches
Source sentences
Summary
These interchanges made up 37.3% of the total population and were observed to have 93% tolerability.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective chart review of adult patients receiving care through a participating family medicine or endocrinology clinic between January 1, 2022, and November 30, 2022 at a major academic medical center.
Summary · context
The most common interchanges were dulaglutide 4.5 mg to tirzepatide 7.5 mg, dulaglutide 4.5 mg to tirzepatide 10 mg, and dulaglutide 3 mg to tirzepatide 7.5 mg.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3941423404
13HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In adult outpatients, pooled incretin analog interchange was estimated to shorten time to maximum dose by a median of 3 months.
In plain wordsIn adult outpatients, pooled drug switches including dulaglutide regimens were linked to a median 3-month reduction in time to maximum dose.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseTime to maximum dose
Study
n: not reported in source
Outcome group
Patterns of use · Whole body
Measurements
Reduction in time to maximum dose
3 months
median
Source sentences
Summary
The interchange of incretin analog was estimated to reduce time to maximum dose by a median of 3 months.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective chart review of adult patients receiving care through a participating family medicine or endocrinology clinic between January 1, 2022, and November 30, 2022 at a major academic medical center.
Summary · context
The most common interchanges were dulaglutide 4.5 mg to tirzepatide 7.5 mg, dulaglutide 4.5 mg to tirzepatide 10 mg, and dulaglutide 3 mg to tirzepatide 7.5 mg.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3941423411
14HumanNot a test of Tirzepatide aloneObservational studyOther
In adult outpatients, pooled incretin analog interchange was estimated to shorten time to maximum dose by a median of 3 months.
In plain wordsIn adult outpatients, pooled drug switches including tirzepatide regimens were linked to a median 3-month reduction in time to maximum dose.
Peptide
Tirzepatide
Outcome
DecreaseTime to maximum dose
Study
n: not reported in source
Outcome group
Patterns of use · Whole body
Measurements
Reduction in time to maximum dose
3 months
median
Source sentences
Summary
The interchange of incretin analog was estimated to reduce time to maximum dose by a median of 3 months.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a retrospective chart review of adult patients receiving care through a participating family medicine or endocrinology clinic between January 1, 2022, and November 30, 2022 at a major academic medical center.
Summary · context
The most common interchanges were dulaglutide 4.5 mg to tirzepatide 7.5 mg, dulaglutide 4.5 mg to tirzepatide 10 mg, and dulaglutide 3 mg to tirzepatide 7.5 mg.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3941423412

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.